| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | FGCP; FOLH 1; GCP 2; GCPII; mGCP; NAALADase I; PSM; PSMA |
| Entrez GeneID | 2346 |
| WB Predicted band size | Calculated MW: 84 kDa; Observed MW: 100 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse |
| Immunogen | A synthetic peptide of human PSMA |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于PSMA抗体的3篇代表性文献及其摘要：
1. **文献名称**：*"Prostate-Specific Membrane Antigen (PSMA)-Targeted Therapeutics for Prostate Cancer"*
**作者**：Wright, G.L. et al.
**摘要**：综述了PSMA抗体在前列腺癌诊疗中的应用，包括基于抗体的靶向药物递送(如抗体-药物偶联物)和分子影像探针开发，强调其肿瘤特异性结合优势及临床转化潜力。
2. **文献名称**：*"177Lu-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer"*
**作者**：Hofman, M.S. et al. (TheraP Trial, 2021)
**摘要**：报道III期临床试验结果，证明177Lu标记的PSMA抗体偶联物可显著延长转移性去势抵抗性前列腺癌患者的无进展生存期，验证了放射性配体疗法的临床有效性。
3. **文献名称**：*"PSMA-Targeted PET Imaging for Prostate Cancer: Comparison with Conventional Imaging"*
**作者**：Eiber, M. et al.
**摘要**：通过多中心研究证实，基于PSMA抗体的PET-CT成像在检测前列腺癌转移病灶时，敏感性和特异性均显著优于传统影像技术(如MRI/骨扫描)，改变了疾病分期标准。
4. **文献名称**：*"A Bispecific PSMAxCD3 Antibody for T Cell-Mediated Killing of Prostate Cancer Cells"*
**作者**：Gerhardt, C.A. et al.
**摘要**：开发了一种双特异性PSMA/CD3抗体，可同时结合肿瘤细胞和T细胞，在临床前模型中诱导特异性T细胞活化及肿瘤消退，为免疫治疗提供新策略。
---
**注**：以上文献均聚焦于PSMA抗体的核心应用领域(靶向治疗、影像诊断、免疫疗法)，选取近年高影响力研究及综述，用户可据此快速了解领域进展。
Prostate-Specific Membrane Antigen (PSMA) is a transmembrane glycoprotein highly expressed in prostate cancer cells, with limited presence in normal tissues. Its gene, *FOLH1*, encodes a 750-amino-acid protein with a glutamate-carboxypeptidase enzymatic domain, involved in folate metabolism and cell signaling. PSMA's overexpression in prostate cancer, particularly in advanced, metastatic, or hormone-resistant cases, has made it a pivotal biomarker and therapeutic target.
PSMA-targeting antibodies, engineered to bind specifically to its extracellular domain, have revolutionized diagnostic and therapeutic approaches. In diagnostics, radiolabeled PSMA antibodies (e.g., ⁶⁸Ga-PSMA-11) enable precise PET/CT imaging for tumor localization and staging. Therapeutically, antibody-drug conjugates (ADCs) and radioimmunoconjugates (e.g., ¹⁷⁷Lu-PSMA-617) deliver cytotoxic payloads directly to cancer cells, sparing healthy tissues. These therapies show promise in extending survival in castration-resistant prostate cancer.
Beyond prostate cancer, PSMA expression in neovasculature of other solid tumors (e.g., glioblastoma, renal cell carcinoma) has expanded its clinical relevance. Challenges remain, including tumor heterogeneity and variable antigen density, driving research into bispecific antibodies, combination therapies, and improved imaging agents. Ongoing trials aim to optimize dosing, reduce toxicity, and explore PSMA's role in immunotherapy, solidifying its status as a cornerstone of precision oncology.
×
